Table 2. Results for measurement of plasma fibronectin using enzyme-linked immunosorbent assays (ELISA) in the diagnosis of breast cancer in test set.
| AUC (95%CI) | Sensitivity (%) | Specificity (%) | LR + | NR − | |
|---|---|---|---|---|---|
| Method 1 | |||||
| BC vs HC+bB+NC* | 0.810 (0.758-0.862) | 65.1% | 83.2% | 3.88 | 0.42 |
| BC vs bB+NC | 0.746 (0.680-0.811) | 63.4% | 78.8% | 2.99 | 0.46 |
| Early-BC vs HC+bB+NC | 0.815 (0.761-0.869) | 64.4% | 84.2% | 4.08 | 0.42 |
| Early−BC vs bB+NC | 0.754 (0.685-0.822) | 65.9% | 77.3% | 2.90 | 0.44 |
| Method 2 | |||||
| BC vs HC+bB+NC | 0.773 (0.721-0.834) | 69.2% | 73.3% | 2.59 | 0.42 |
| BC vs bB+NC | 0.710 (0.641-0.779) | 60.4% | 75.8% | 2.49 | 0.52 |
| Early-BC vs HC+bB+NC | 0.779 (0.719-0.838) | 72.7% | 71.3% | 2.53 | 0.38 |
| Early−BC vs bB+NC | 0.713 (0.640-0.787) | 59.9% | 75.8% | 2.47 | 0.53 |
*
BC, breast cancer; HC, Healthy controls; bB, benign breast tumors; NC, non-cancerous diseases; Early−- BC, early stage breast cancer.